Franklin Covey Co. (FC) Forms $26.05 Double Bottom; Sucampo Pharmaceuticals Class A (SCMP) Shorts Increased By 2.14%

February 15, 2018 - By Stephen Andrade

Franklin Covey Co. (FC) formed double bottom with $25.27 target or 3.00% below today’s $26.05 share price. Franklin Covey Co. (FC) has $361.01 million valuation. The stock decreased 0.57% or $0.15 during the last trading session, reaching $26.05. About 56,286 shares traded. Franklin Covey Co. (NYSE:FC) has risen 33.77% since February 15, 2017 and is uptrending. It has outperformed by 17.07% the S&P500.

Sucampo Pharmaceuticals Class A (NASDAQ:SCMP) had an increase of 2.14% in short interest. SCMP’s SI was 4.69 million shares in February as released by FINRA. Its up 2.14% from 4.59 million shares previously. With 754,100 avg volume, 6 days are for Sucampo Pharmaceuticals Class A (NASDAQ:SCMP)’s short sellers to cover SCMP’s short positions. The SI to Sucampo Pharmaceuticals Class A’s float is 17.18%. It closed at $18 lastly. It is down 5.30% since February 15, 2017 and is downtrending. It has underperformed by 22.00% the S&P500.




Among 7 analysts covering Franklin Covey Company (NYSE:FC), 5 have Buy rating, 0 Sell and 2 Hold. Therefore 71% are positive. Franklin Covey Company had 8 analyst reports since November 5, 2015 according to SRatingsIntel. The stock of Franklin Covey Co. (NYSE:FC) earned “Market Perform” rating by William Blair on Thursday, November 5. The firm has “Buy” rating given on Thursday, November 5 by TH Capital. The company was downgraded on Wednesday, December 28 by Barrington Research. The firm has “Buy” rating given on Sunday, November 12 by Roth Capital. B. Riley & Co maintained Franklin Covey Co. (NYSE:FC) on Friday, November 10 with “Buy” rating. Roth Capital maintained the stock with “Buy” rating in Thursday, November 5 report. The stock has “Buy” rating by Barrington on Tuesday, January 9. The stock of Franklin Covey Co. (NYSE:FC) has “Buy” rating given on Tuesday, November 7 by FBR Capital.

Since September 1, 2017, it had 0 buys, and 2 selling transactions for $69,744 activity. PETERSON JOEL CLINTON had sold 1,792 shares worth $36,424 on Monday, October 2.

Investors sentiment decreased to 1.04 in Q3 2017. Its down 0.28, from 1.32 in 2017Q2. It dived, as 3 investors sold Franklin Covey Co. shares while 20 reduced holdings. 6 funds opened positions while 18 raised stakes. 6.76 million shares or 5.00% less from 7.12 million shares in 2017Q2 were reported. California Public Employees Retirement reported 19,732 shares. State Common Retirement Fund accumulated 11,200 shares or 0% of the stock. Tiaa Cref Investment Mgmt Limited Liability Corp invested in 25,019 shares or 0% of the stock. Texas-based Centaur Ptnrs Lp has invested 4.83% in Franklin Covey Co. (NYSE:FC). Renaissance Tech Ltd Llc accumulated 91,573 shares. Schwab Charles Investment Management Inc stated it has 51,359 shares or 0% of all its holdings. Vanguard Group Inc holds 474,206 shares or 0% of its portfolio. 11,011 were accumulated by Wells Fargo & Com Mn. Geode Mngmt Limited Liability Company reported 0% of its portfolio in Franklin Covey Co. (NYSE:FC). Ameritas Investment Partners stated it has 0% in Franklin Covey Co. (NYSE:FC). Moreover, Bnp Paribas Arbitrage Sa has 0% invested in Franklin Covey Co. (NYSE:FC). Nationwide Fund Advsrs accumulated 0% or 9,767 shares. Legal & General Grp Public Ltd Co reported 2,858 shares stake. American Int Gru Inc Inc reported 6,509 shares. Jpmorgan Chase & reported 82,322 shares.

Among 13 analysts covering Sucampo Pharma (NASDAQ:SCMP), 4 have Buy rating, 0 Sell and 9 Hold. Therefore 31% are positive. Sucampo Pharma had 46 analyst reports since August 6, 2015 according to SRatingsIntel. Mizuho maintained the stock with “Neutral” rating in Monday, January 18 report. The rating was maintained by WallachBeth Capital with “Hold” on Thursday, August 6. The company was downgraded on Tuesday, December 26 by FBR Capital. The rating was maintained by Maxim Group with “Buy” on Wednesday, August 26. The company was initiated on Friday, November 20 by Jefferies. The firm earned “Hold” rating on Wednesday, January 3 by Mizuho. On Monday, August 24 the stock rating was initiated by H.C. Wainwright with “Buy”. Jefferies maintained Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) on Wednesday, October 18 with “Hold” rating. Nomura downgraded the shares of SCMP in report on Friday, January 26 to “Neutral” rating. The company was maintained on Friday, June 9 by Jefferies.

Since September 11, 2017, it had 0 insider purchases, and 3 sales for $24.83 million activity. Another trade for 1.00 million shares valued at $12.00M was made by Ueno Ryuji on Monday, September 11. The insider Kuno Sachiko sold 1.00M shares worth $12.00 million. Kiener Peter A sold $825,000 worth of Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) on Thursday, December 7.

Investors sentiment increased to 1.65 in 2017 Q3. Its up 0.32, from 1.33 in 2017Q2. It increased, as 14 investors sold Sucampo Pharmaceuticals, Inc. shares while 40 reduced holdings. 31 funds opened positions while 58 raised stakes. 29.83 million shares or 20.72% more from 24.71 million shares in 2017Q2 were reported. Gotham Asset Mngmt Ltd Liability Corp holds 0.01% or 39,830 shares in its portfolio. Etrade Mgmt Limited Co holds 0.04% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 105,008 shares. Vanguard stated it has 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Panagora Asset Mgmt owns 164,412 shares. Hartford Inv Management Comm accumulated 13,950 shares. Alps Advsr Inc has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 45,847 shares. State Of Wisconsin Board has invested 0% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Alphamark Advisors Ltd Limited Liability Company has invested 0.49% in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Pnc Service, a Pennsylvania-based fund reported 5,440 shares. Principal Fin Gru invested 0% of its portfolio in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP). Moreover, Connor Clark And Lunn Inv Mngmt Ltd has 0% invested in Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) for 10,025 shares. Prelude Mgmt Ltd Liability Corporation invested in 6,300 shares or 0.01% of the stock. 64,800 were accumulated by Adams Diversified Equity Fund Incorporated. Royal State Bank Of Canada holds 0% or 34,030 shares. Employees Retirement Association Of Colorado accumulated 8,353 shares.

Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing, identifying, acquiring, and marketing medicines that meet unmet medical needs, primarily in gastroenterology, ophthalmology, and oncology-related disorders in the United States, Japan, Switzerland, and internationally. The company has market cap of $847.54 million. The companyÂ’s marketed product includes AMITIZA , a ClC-2 chloride channel activator for the treatment of chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation in adult women (IBS-C), and opioid-induced constipation (OIC)in patients with chronic non-cancer related pain; and RESCULA (unoprostone isopropyl), a big potassium channel activator for the treatment of glaucoma and ocular hypertension. It currently has negative earnings. The Company’s product candidates in clinical development stage comprise Lubiprostone that is in Phase III clinical trials for the treatment of pediatric functional constipation and (IBS-C); and completed Phase III clinical trials for the treatment of (CIC) in adults, IBS-C in adult women, and OIC in patients with chronic non-cancer pain, as well as CPP-1X/sulindac combination product, which has completed Phase III clinical trials for the treatment of familial adenomatous polyposis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: